Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30155362 | 0.80 | SIGMAR1 (0.36) | LMNAPOLBSMN1; SMN2 | |
| SCHEMBL30155305 | 0.80 | SIGMAR1 (0.33) | LMNAPOLBSMN1; SMN2 | |
| SCHEMBL6340824 | 0.76 | POLB (0.41) | LMNAPOLBSMN1; SMN2TSHRRECQL | |
| SCHEMBL29535838 | 0.71 | POLB (0.45) | LMNAPOLBSMN1; SMN2TSHRRECQL | |
| SCHEMBL6820687 | 0.70 | POLB (0.44) | LMNAPOLBSMN1; SMN2TSHRRECQL | |
| SCHEMBL1972696 | 0.69 | POLB (0.41) | LMNAPOLBSMN1; SMN2TSHRRECQL | |
| SCHEMBL5746419 | 0.69 | GAA (0.34) | LMNAPOLBSMN1; SMN2TSHR | |
| SCHEMBL22276816 | 0.68 | SMN1; SMN2 (0.38) | LMNAPOLBSMN1; SMN2TSHRRECQL | |
| SCHEMBL30801324 | 0.68 | SMN1; SMN2 (0.50) | LMNAPOLBSMN1; SMN2TSHR | |
| SCHEMBL31425393 | 0.68 | LMNA (0.32) | LMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359081-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |